Beijing 302 Hospital

This study tests a drug combination (venetoclax plus a hypomethylating agent) followed by an infusion of immune cells from a partially matched donor for people with intermediate- to high-risk myelodysplastic syndromes who cannot have a standard stem cell transplant. The goal is t…

This study tests a combination of five drugs (venetoclax, azacitidine, cytarabine, idarubicin, and G-CSF) as a first treatment for adults aged 18-70 with acute myeloid leukemia who are healthy enough for strong chemotherapy. The goal is to see how many patients achieve complete r…

This early-phase study is for people with relapsed or refractory leukemia, meaning their cancer has returned or not responded to standard treatments. The approach combines chemotherapy with an infusion of immune cells from a partially matched donor, given as a bridge to a stem ce…

This study tests whether a non-invasive therapy called TEAS (mild electrical stimulation on the skin) can reduce side effects from sedation during an ERCP, a procedure to examine the bile and pancreatic ducts. About 130 adults scheduled for ERCP will receive either active TEAS or…